← All drugs Report issue

nilk-2301

mAbexperimentalBi-specific

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

0

Phase 3

0

Phase 4

0

Earliest trial started Apr 12, 2024 (NCT06663839)

Timeline

2020s

Jan 1, 2024
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Colorectal Neoplasms · Phase 1

Mechanism of action

T-cell surface glycoprotein CD3 epsilon chainACTIVATOR
CD3E activator
- T-cell surface glycoprotein CD3 epsilon chain (CD3E) ↗
Carcinoembryonic antigen-related cell adhesion molecule 5INHIBITOR
CEACAM5 inhibitor
- Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) ↗

Chemistry & pharmacology

Multi-specific: Yes (Bi-specific)

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT06663839	Phase 1	Apr 12, 2024	NovImmune SA

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
NovImmune SA	For profit	1	1	1	2024

1 organizations

Page 1 / 1